Abstract
Stem cell models of malignant tumors have been based on the existence of three categories of cells within the total tumor cell population: (a) proliferating, self-renewing stem cells, (b) proliferating, non-self-renewing (transitional) cells and (c) non-proliferating, differentiated (end) cells. In 1984 we introduced the concept of two subpopulations of tumor stem cells (TSC; Fig. 1) [1]. One of these we refer to as the primitive or ancestral TSC (ATSC), which can remain out of cycling in Go for prolonged periods of time. ATSC have a very long life span (almost unlimited). We hypothesized that late metastases, arising clinically more than 5 years after removal of the primary tumor, derive from these. The second we have called the committed TSC (CTSC), which has a restricted and transient development potential (limited to 4–5 years). In 1984 it was believed that a committed precursor could not retain its stem cell capacity. Indeed, normal stem cells were defined only by their very high reproductive capacity and multilineage differentiation potential.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Jasmin C, Judde JG, Georgoulias V, Smadja-Joffe F, Poupon MF (1984) Models for adjuvant therapy. In: Jones SE, Salmon SE (eds) Adjuvant therapy of cancer. Grune and Stratton, Philadelphia, pp 35–45
Keller G, Snodgrass R (1990) Life span of multipotential hematopoietic stem cell in vivo. J Exp Med 171:10–47
Moore MAS (1991) Clinical implications of positive and negative hematopoietic stem cell regulators. Blood 78:1–19
Simpson-Herren L, Standford AH, Holmquist JP (1976) Effect of surgery on the cell kinetics of residual tumor. Cancer Treat Rep 60:1749–1760
Gunduz N, Fisher B, Saffer EA (1979) Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res 39:3861–3865
Fisher B, Gunduz N, Saffer EA et al. (1983) Influence of their interval between primary tumor removal and chemotherapy on kinetics and growth of metastasis. Cancer Res 43:1482–1488
Diskson RB, Huff KK, Spencer EM, Lippman ME (1986) Induction of epidermal growth factor-related polypeptides by 17-oestradiol in MCF-7 human breast cancer cells. Endocrinology 118:138–141
Hrushesky WJM, Bluming AZ, Gruber SA, Sothern RB (1989) Menstrual influence on surgical cure of breast cancer. Lancet 2:949–952
Senie RT, Rosen PP, Rhodes P, Lesser ML (1990) Prognosis of primary breast cancer in relation to time of diagnostic surgery during the menstrual cycle. Breast Cancer Res Treat 16:14–16
Badwe RA, Fentiman IS, Saad Z, Bentley A, Richards MA, Gregory W, Chaudary MA, Rubens RD (1991) Surgical procedures, menstrual cycles phase, and prognosis in operable breast cancer. Lancet 338:815–816
Knabbe C, Lippman ME, Wakefield LM et al. (1987) Evidence that transforming growth factor beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48:417–428
Fisher B, Redmond C, Brown A et al. (1986) Adjuvant chemotherapy with or without tamoxifen in the treatment of primary breast cancer: five-year results from the NSABP trial. J Clin Oncol 4:459–471
Early Breast Cancer Trialist’s Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 1–15, 71–84
The International Breast Cancer Study Group (1990) Late effect of adjuvant oophorectomy and chemotherapy upon premenopausal breast cancer patients. Ann Oncol 1:30–35
Fendl KC, Zimniski J (1992) Role of tamoxifen in the induction of hormone- independent rat mammary tumors. Cancer Res 52:235–237
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer-Verlag Berlin · Heidelberg
About this paper
Cite this paper
Jasmin, C. (1993). Tumor Stem Cells and the Curability of Early Human Breast Cancer. In: Senn, HJ., Gelber, R.D., Goldhirsch, A., Thürlimann, B. (eds) Adjuvant Therapy of Breast Cancer IV. Recent Results in Cancer Research, vol 127. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-84745-5_2
Download citation
DOI: https://doi.org/10.1007/978-3-642-84745-5_2
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-84747-9
Online ISBN: 978-3-642-84745-5
eBook Packages: Springer Book Archive